Hydrogen Gas Improves RNA Drug Delivery for Lung Scarring Treatment
- Authors
- Chang Liu, Xidong Tian, Zhenping Wang, Judith Choi Wo Mak, Shirui Mao, Tzu-Ming Liu, Ying Zheng
- Journal
- Science Advances
- Year
- 2025
- DOI
- 10.1126/sciadv.adt2752
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Pulmonary Fibrosis
- Body System
- Respiratory
TL;DR
Scientists have developed a new inhalation device that delivers RNA therapy effectively to the lungs to treat pulmonary fibrosis, a lung disease, by combining a special aerosol system with therapeutic hydrogen gas.
Key Finding
Hydrogen gas delivered alongside nanoparticles disrupts the airway mucus barrier, significantly improving the delivery of RNA therapy to fibrotic lung tissue in mice.
Summary
Researchers developed a new system to deliver RNA-based medicine directly into the lungs to treat pulmonary fibrosis (scarring of lung tissue). The system uses hydrogen gas to help break down the protective mucus layer in airways, allowing specially designed nanoparticles (tiny particles carrying genetic material) to reach damaged lung tissue more effectively. In mouse studies, this approach successfully blocked the biological signals that cause lung scarring and triggered repair processes.
Practical Takeaway
This is early-stage research conducted only in mice, so it cannot yet be applied to human treatment. The study suggests that combining hydrogen gas with RNA-based therapies may be a promising approach for pulmonary fibrosis, but human clinical trials would be needed to determine safety and effectiveness in people.
Abstract
Nebulized RNA therapies are well suited for treating respiratory diseases, in particular pulmonary fibrosis (PF); however, effective delivery remains challenging. In this study, we present a highly efficient aerosol inhalation system that enables high levels of in vivo transfection efficiency in lung macrophages, yielding durable responses against PF. First, we established a nose-only aerosol inhalation device integrated with a hydrogen supplement system. This setup enables the precise administration of lipid nanoparticles (LNPs) at a controlled low dose, while simultaneously delivering the optimal concentration of therapeutic hydrogen gas. We further developed a hybrid lipid NP (HNP) by hybridizing a pH-dependent charge-inverting lipid film with apoptotic T cell membranes to enhance endosomal escape and trigger macrophage production of hepatocyte growth factor for lung repair. We demonstrated that the hydrogen flow-induced shear stresses disrupt the NP-mucus interaction, enhancing the deposition of aerosolized HNPs/TGFβ1 siRNA within fibrotic lung lesions, effectively blocking fibrogenic signaling pathways and offering a clinically viable strategy for combating PF.